Granules India Limited has announced its audited financial results for the fourth quarter and full financial year ended March 31, 2026, alongside a final dividend recommendation of Rs. 1.75 per equity share. For the quarter ended March 31, 2026, the company reported consolidated revenue from operations of Rs. 14,706.0 million, representing a 19.83% increase compared to the previous quarter’s Rs. 12,272.2 million. On a Year-over-Year (YoY) basis, revenue surged by 22.81% from Rs. 11,974.0 million in the corresponding quarter of the previous year. The consolidated Net Profit for Q4 FY26 stood at Rs. 2,015.6 million, marking a substantial 34.19% growth from the Rs. 1,502.1 million recorded in Q3 FY26. Compared to Q4 FY25, the profit after tax rose by 32.57% from Rs. 1,520.3 million.

Granules India Limited is a vertically integrated pharmaceutical company based in Hyderabad, India, with a global presence across the manufacturing value chain, including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediaries (PFIs), and Finished Dosages (FDs). The company operates over 10 manufacturing facilities located in India and the United States, supplying key products like Paracetamol, Metformin, and Guaifenesin to markets in North America, Europe, and Asia. In late 2025, the company expanded its footprint by announcing the acquisition of Optus 1039 GmbH and setting up advanced R&D Centers of Excellence at IITH to drive innovation-led transformation. Prominent institutional investors in the company include the Life Insurance Corporation of India (LIC), which held a 5.22% stake as of early 2026.